AIDS science at 30: 'Cure' now part of lexicon

May 18, 2013 by Richard Ingham

Big names in medicine are set to give an upbeat assessment of the war on AIDS on Tuesday, 30 years after French researchers identified the virus that causes the disease.

Scientists will pay tribute to the astonishing success of and highlight steps being taken towards a cure—a goal once deemed all but out of reach.

Entitled "Imagine the Future," the three-day conference builds on the 30th anniversary on Monday of the isolation of the (HIV).

The Nobel-winning achievement, by a team led by Luc Montagnier of France's Pasteur Institute, unmasked a killer.

Then began the drive to treat the disease and halt its spread.

"The discovery of HIV in 1983 and the proof that it was the cause of AIDS in 1984 were the first major that provided a specific target for blood-screening tests and opened the doorway to the development of antiretroviral medications," said Anthony Fauci, director of the US National Institute of Allergy and Infectious Diseases (NIAID).

Introduced in 1996, after many years of frantic drug research, are saving the lives of millions of people infected with HIV and helping to contain the virus' spread, Fauci said in an email.

By suppressing viral levels, antiretrovirals can prevent HIV being transmitted by pregnant women to their unborn children, and by infected people to their sexual partners.

But there have also been setbacks, particularly in the quest for a vaccine.

Only last month, US authorities halted the latest clinical trial—launched in 2009—after the prototype formula failed to prevent infection.

Finding antibodies that are able to identify the slippery, mutating virus has proven to be almost as hard as the proverbial search for a needle in a haystack.

" continues to suffer from setbacks—but pursue a vaccine we must if we are to truly see the end of AIDS," said Adeeba Kamarulzaman, a professor of infectious diseases at the University of Malaya, who will co-chair a global conference on AIDS science in Kuala Lumpur in June.

Counter-intuitively, the main hope nowadays seems to rest on a cure.

Three years ago, Francoise Barre-Sinoussi—a 2008 Nobel co-recipient with Montagnier—mapped a strategy for attacking HIV's "reservoir."

This is the cellular bolthole where the virus lurks after being pounded with antiretrovirals. Once the drugs are stopped, the virus re-emerges and spreads once more through the bloodstream.

"The great challenge will be to fully understand where the virus hides, how it manages to stay hidden so effectively and how to lure it out of its hiding place. We've learnt a lot about this in the past few years," said Sharon Lewin, a professor at Monash University in Melbourne, Australia.

'Functional cure'

Lewin is part of a team cautiously experimenting with an anti-cancer drug to flush out the virus that destroys the immune system and exposes infected people to pneumonia, TB, and other opportunistic diseases.

In trials on 20 patients, the cancer drug awoke the dormant virus in 90 percent of volunteers. The ultimate goal is to kill the newly-exposed virus, leaving the cell it hid in to die eventually of old age.

"We do have drugs that seem to wake up the virus but these are only the first steps in ultimately clearing it out completely," said Lewin.

Two other small studies using antiretrovirals at a very early stage of infection, before viral levels build up, have excited hopes of a "functional cure."

One involved a baby in Mississippi, apparently cleared of the virus after being given aggressive antiretroviral treatment within 30 hours of birth.

"It is certainly a very exciting finding, but this is only a single case and additional studies are needed to determine whether the circumstances of this particular case can be replicated among other HIV-exposed children," said Fauci.

The other is a small French study of 14 HIV patients, known as the VISCONTI cohort, given drugs very soon—within 10 weeks—after infection. Treatment normally starts only once the immune system becomes compromised, sometimes years after infection.

The VISCONTI group stopped taking the daily drugs after about three years, and have remained healthy.

And crucially, none of the individuals are among that rare group of people—fewer than one percent of the population—who seem able to naturally stave off HIV and are known as "natural" or "elite controllers."

AIDS has killed 30 million people.

An estimated 34 million people are infected with HIV worldwide, and about 1.8 million die every year.

A year after the Montagnier team's historic publication in Science on May 20, 1983, a team led by Robert Gallo of the United States published similar findings—triggering an acrimonious debate with research funding and prestige at stake.

It turned out that Gallo had worked on a viral sample originally sent to him by Montagnier.

Credit for isolating HIV thus went to the French team, but Gallo was recognised for determining that the caused AIDS, something the Montagnier study was not clear on.

Explore further: Researchers make HIV wake up call

Related Stories

Researchers make HIV wake up call

March 4, 2013
Researchers have moved a step closer to finding a cure for HIV by successfully luring the 'sleeping' virus out of hiding in infected cells.

French patients keep HIV at bay despite stopping drugs (Update)

March 14, 2013
A small French study of 14 HIV patients who have remained healthy for years after stopping drug treatment offers fresh evidence that early medical intervention may lead to a "functional cure" for AIDS, researchers said Thursday.

Latest HIV vaccine doesn't work; govt halts study (Update)

April 25, 2013
The latest bad news in the hunt for an AIDS vaccine: The government halted a large U.S. study on Thursday, saying the experimental shots are not preventing HIV infection.

HIV 'cure' looks 'promising,' Danish scientists contend

April 29, 2013
(HealthDay)—Danish scientists testing a novel HIV treatment in human trials contend that they're confident their strategy will result in a cure for the AIDS-causing virus, according to news reports.

AIDS cure may have two main pathways: experts (Update)

July 24, 2012
Investigators are looking into two main paths toward a cure for AIDS, based on the stunning stories of a small group of people around the world who have been able to overcome the disease.

HIV no barrier to getting liver transplant, study finds

May 17, 2013
(HealthDay)—Liver transplants to treat a common type of liver cancer are a viable option for people infected with HIV, according to new research.

Recommended for you

New injectable antiretroviral treatment proved to be as effective as standard oral therapy

August 3, 2017
Intramuscularly administered antiretroviral therapy (ART) may be as effective for HIV treatment as current oral therapies. This is the main conclusion of a Phase II clinical trial carried out by 50 research centers around ...

Research finds home-based kit would increase HIV testing

July 31, 2017
Research led by William Robinson, PhD, Associate Research Professor of Behavioral & Community Health Sciences at LSU Health New Orleans School of Public Health, has found that 86% of heterosexuals who are at high risk for ...

Scientists divulge latest in HIV prevention

July 25, 2017
A far cry from the 1990s "ABC" campaign promoting abstinence and monogamy as HIV protection, scientists reported on new approaches Tuesday allowing people to have all the safe sex they want.

Girl's HIV infection seems under control without AIDS drugs

July 24, 2017
A South African girl born with the AIDS virus has kept her infection suppressed for more than eight years after stopping anti-HIV medicines—more evidence that early treatment can occasionally cause a long remission that, ...

Meds by monthly injection might revolutionize HIV care (Update)

July 24, 2017
Getting a shot of medication to control HIV every month or two instead of having to take pills every day could transform the way the virus is kept at bay.

Candidate AIDS vaccine passes early test

July 24, 2017
The three-decade-old quest for an AIDS vaccine received a shot of hope Monday when developers announced that a prototype triggered the immune system in an early phase of human trials.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.